Aegerion Pharmaceuticals
AEGR
AEGR was delisted on the 29th of November, 2016.
0 hedge funds and large institutions have $0 invested in Aegerion Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 58 closing their positions.
84.85% less ownership
Funds ownership: 84.85% → 0% (-85%)
100% less funds holding
Funds holding: 58 → 0 (-58)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $74.5M
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 58
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$16.9M |
| 2 |
BC
Broadfin Capital
New York
|
-$13M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.52M |
| 4 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$7.87M |
| 5 |
Renaissance Technologies
New York
|
-$5.1M |
AEGR Hedge Fund Activity: Q4 2016 in Review
0 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Aegerion Pharmaceuticals (AEGR) for Q4 2016, worth a combined $0 — down 100% from $84.5M a quarter earlier.
Sellers outnumbered buyers: 58 funds closed out of AEGR and 0 opened new positions — a net loss of 58 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Scopia Capital Management, exiting entirely with an estimated $16.9M sold.
- 0 institutional investors held Aegerion Pharmaceuticals (AEGR) as of Q4 2016, down from 58 in Q3 2016.
- Funds reported $0 of Aegerion Pharmaceuticals stock for Q4 2016, down 100% quarter-over-quarter.
- 0 funds opened new Aegerion Pharmaceuticals positions in Q4 2016 and 58 closed out, a net change of -58 holders.
- The largest Aegerion Pharmaceuticals seller in Q4 2016 was Scopia Capital Management, an estimated $16.9M sold.
Based on aggregated 13F filings for Q4 2016.